Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?
Daniël Hoyer, Laura H. Jacobson
Neuropeptides (2013) Vol. 47, Iss. 6, pp. 477-488
Closed Access | Times Cited: 107

Showing 1-25 of 107 citing articles:

Alcohol use disorder and sleep disturbances: a feed-forward allostatic framework
George F. Koob, Ian M. Colrain
Neuropsychopharmacology (2019) Vol. 45, Iss. 1, pp. 141-165
Open Access | Times Cited: 202
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
Aging drives cerebrovascular network remodeling and functional changes in the mouse brain
Hannah Bennett, Qingguang Zhang, Yuan-Ting Wu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 21
A Selective Orexin-1 Receptor Antagonist Attenuates Stress-Induced Hyperarousal without Hypnotic Effects
Pascal Bonaventure, Sujin Yun, Philip L. Johnson, et al.
Journal of Pharmacology and Experimental Therapeutics (2015) Vol. 352, Iss. 3, pp. 590-601
Open Access | Times Cited: 94
Orexins and fear: implications for the treatment of anxiety disorders
África Flores, Rocío Saravia, Rafaël Maldonado, et al.
Trends in Neurosciences (2015) Vol. 38, Iss. 9, pp. 550-559
Open Access | Times Cited: 92
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
Emerging drugs for neuropathic pain
Ian Gilron, Anthony H. Dickenson
Expert Opinion on Emerging Drugs (2014) Vol. 19, Iss. 3, pp. 329-341
Closed Access | Times Cited: 73
Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia
Pascal Bonaventure, Jonathan Shelton, Sujin Yun, et al.
Journal of Pharmacology and Experimental Therapeutics (2015) Vol. 354, Iss. 3, pp. 471-482
Open Access | Times Cited: 71
Neuroprotection by Orexin-A via HIF-1α induction in a cellular model of Parkinson's disease
Ya Feng, Te Liu, Xin-Qun Li, et al.
Neuroscience Letters (2014) Vol. 579, pp. 35-40
Closed Access | Times Cited: 71
Suvorexant
Kunal V. Patel, Anthony V. Aspesi, Kirk E. Evoy
Annals of Pharmacotherapy (2015) Vol. 49, Iss. 4, pp. 477-483
Closed Access | Times Cited: 65
Suvorexant: The first orexin receptor antagonist to treat insomnia
Ashok Kumar Dubey, Shailendra Handu, Pramod Kumari Mediratta
Journal of Pharmacology and Pharmacotherapeutics (2015) Vol. 6, Iss. 2, pp. 118-121
Open Access | Times Cited: 64
Effects of orexin receptor antagonism on human sleep architecture: A systematic review
Jacob Clark, Maddison L. Brian, Sean P. A. Drummond, et al.
Sleep Medicine Reviews (2020) Vol. 53, pp. 101332-101332
Closed Access | Times Cited: 54
Sleep disorders related to nutrition and digestive diseases: a neglected clinical condition
Filippo Vernia, Mirko Di Ruscio, A Ciccone, et al.
International Journal of Medical Sciences (2020) Vol. 18, Iss. 3, pp. 593-603
Open Access | Times Cited: 53
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
Neurobiology of the Orexin System and Its Potential Role in the Regulation of Hedonic Tone
Martin A. Katzman, Matthew P. Katzman
Brain Sciences (2022) Vol. 12, Iss. 2, pp. 150-150
Open Access | Times Cited: 30
OREXIN 1 AND 2 RECEPTOR INVOLVEMENT IN CO2-INDUCED PANIC-ASSOCIATED BEHAVIOR AND AUTONOMIC RESPONSES
Philip L. Johnson, Lauren M. Federici, Stephanie D. Fitz, et al.
Depression and Anxiety (2015) Vol. 32, Iss. 9, pp. 671-683
Open Access | Times Cited: 62
Sleep, chronic pain, and opioid risk for apnea
Serguei Marshansky, Pierre Mayer, Dorrie Rizzo, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2017) Vol. 87, pp. 234-244
Closed Access | Times Cited: 60
Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases?
Craig M. Smith, Andrew W. Walker, Ihaia T. Hosken, et al.
Frontiers in Pharmacology (2014) Vol. 5
Open Access | Times Cited: 59
Neurobiological Risk Factors for the Development of Internet Addiction in Adolescents
Sergey Tereshchenko, Э. В. Каспаров
Behavioral Sciences (2019) Vol. 9, Iss. 6, pp. 62-62
Open Access | Times Cited: 53
Suvorexant for the treatment of insomnia
Laura H. Jacobson, Gabrielle E. Callander, Daniël Hoyer
Expert Review of Clinical Pharmacology (2014) Vol. 7, Iss. 6, pp. 711-730
Closed Access | Times Cited: 52
A sleeping giant: Suvorexant for the treatment of alcohol use disorder?
Erin J. Campbell, Nathan J. Marchant, Andrew J. Lawrence
Brain Research (2018) Vol. 1731, pp. 145902-145902
Closed Access | Times Cited: 50
Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration
Clemens Muehlan, Sander Brooks, Rob Zuiker, et al.
European Neuropsychopharmacology (2019) Vol. 29, Iss. 7, pp. 847-857
Closed Access | Times Cited: 49
Orexin Signaling: A Complex, Multifaceted Process
Natasha C. Dale, Daniël Hoyer, Laura H. Jacobson, et al.
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 26
Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease
J Kron, Ryan J. Keenan, Daniël Hoyer, et al.
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 359-386
Open Access | Times Cited: 15
Effect of a dual orexin receptor antagonist on Alzheimer's disease: Sleep disorders and cognition
Mengzhen Zhou, Shi Tang
Frontiers in Medicine (2023) Vol. 9
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top